Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn,Pam K. Mangat,Elizabeth Garrett-Mayer,Susan Halabi,Elie G. Dib,Daniel Haggstrom,Kathryn B. Alguire,Carmen Julia Calfa,Timothy Lewis Cannon,Pamela A. Crilley,Anu G. Gaba,Alissa S. Marr,Ashish Sangal,Ramya Thota,Kaitlyn R. Antonelli,Samiha Islam,Andrew Lawrence Rygiel,Suanna S. Bruinooge,Richard L. Schilsky

Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

2020

Eugene R. Ahn
Pam K. Mangat
Elizabeth Garrett-Mayer
Susan Halabi
Elie G. Dib
Daniel Haggstrom
Kathryn B. Alguire
Carmen Julia Calfa
Timothy Lewis Cannon
Pamela A. Crilley
Anu G. Gaba
Alissa S. Marr
Ashish Sangal
Ramya Thota
Kaitlyn R. Antonelli
Samiha Islam
Andrew Lawrence Rygiel
Suanna S. Bruinooge
Richard L. Schilsky

PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients w...

Keywords:

CDKN2A
Palbociclib
antitumor activity
Lung cancer
in patient
Oncology
registry study
non small cell
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations